Canada· CA-DIN-02527391
TABRECTA
A capmatinib product containing capmatinib (capmatinib hydrochloride), registered in Canada by NOVARTIS PHARMACEUTICALS CANADA INC. The same ATC class is registered in 4 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Capmatinib is registered in 4 of 19 countries.
Countries holding a registration under ATC L01EX17 (capmatinib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 2 of them publish a price we can compare per daily dose
Capmatinib · ATC L01EX17
4 / 19 countries
- Canada
- Ireland
- Polandprice
- Switzerlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- CAPMATINIB (CAPMATINIB HYDROCHLORIDE)
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Country
- Canada (CA)
- ATC code
- L01EX17
- ATC class
- Capmatinib
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
173 interactions on record for capmatinib.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Capmatinib · interactions on record
173 records
- 28 severe
- 136 moderate
- 9 minor
Most severe, free to view
- EdoxabanB01AF03severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Capmatinib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTABRECTANovartis Europharm Limited, Dublin
- FinlandTabrectaNovartis Europharm Limited
- SpainTABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- United StatesTABRECTANovartis Pharmaceuticals Corporation
- SwitzerlandTabrecta 150 mg, FilmtablettenNovartis Pharma Schweiz AG
- BelgiumTabrecta 150 mgNovartis Europharm
- IrelandTabrecta 150 mg film-coated tabletsNovartis Europharm Limited
- IcelandTabrectaNovartis Europharm Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tabrecta
- Liechtenstein · Tabrecta
- Norway · Tabrecta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eabb25b6-b707-417b-bc89-76128bde1d4f GET /v1/drugs/eabb25b6-b707-417b-bc89-76128bde1d4f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02527391",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01EX17",
"schedule": [
"Prescription"
],
"drug_code": "101646",
"strengths": [
"150 MG"
],
"ahfs_class": null,
"substances": [
"CAPMATINIB (CAPMATINIB HYDROCHLORIDE)"
],
"product_categorization": null
}See everything about capmatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.